You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

LAMISIL AT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Lamisil At patents expire, and what generic alternatives are available?

Lamisil At is a drug marketed by Haleon Us Holdings and is included in two NDAs.

The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.

Drug patent expirations by year for LAMISIL AT
Drug Prices for LAMISIL AT

See drug prices for LAMISIL AT

Recent Clinical Trials for LAMISIL AT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Oregon Health and Science UniversityEarly Phase 1
The Malassezia FoundationEarly Phase 1
Pak Emirates Military HospitalPhase 3

See all LAMISIL AT clinical trials

US Patents and Regulatory Information for LAMISIL AT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Haleon Us Holdings LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Haleon Us Holdings LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Haleon Us Holdings LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LAMISIL AT

International Patents for LAMISIL AT

See the table below for patents covering LAMISIL AT around the world.

Country Patent Number Title Estimated Expiration
Japan S6342612 ⤷  Try a Trial
Hong Kong 148896 Topical composition containing terbinafine ⤷  Try a Trial
Austria 10272 ⤷  Try a Trial
Ireland 781670 ⤷  Try a Trial
Germany 3069633 ⤷  Try a Trial
Slovakia 281615 ⤷  Try a Trial
Ireland 47314 PROPENYL AMINES,PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for LAMISIL AT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0024587 SPC/GB93/096 United Kingdom ⤷  Try a Trial SPC/GB93/096, EXPIRES: 20050805
0024587 93C0136 Belgium ⤷  Try a Trial PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.